Reading ECOR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ECOR free→Reading ECOR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ECOR free→NASDAQHealth CareMedical DevicesSnapshot 2026-06-15
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak, and the company was unprofitable over the past year, so its earnings quality can't be assessed. Management's recent track record has been steady, but risk is elevated, and the sector backdrop is a headwind. Compared with sector peers, ECOR is above typical for the sector. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $9.11. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 0.44x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.37 → $-0.41 (-13.1% / 30d). 1 raised, 4 cut, 5 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$305.
How much price usually moves either way.
On a bad day, this stock has moved -$770.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $4,599.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If sector revenue growth speeds up, it could help ElectroCore's performance. A stronger sector may lift all companies.
Confirms:Sector revenue growth is speeding up again. It is close to 10% year over year.
Disproves:Sector revenue growth is slowing down. It is now below 10% year over year.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for ECOR yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 6, 2026, electroCore, Inc. (the “Company”) issued a press release (i) announcing its financial results for the first quarter ended March 31, 2026, and (ii) providing guidance for the full year of 2026. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated by reference. The information contained in this
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
ECOR ElectroCore Inc | Above typical Show detailsSector percentile: 71 of 100 | — | elevated |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 94 of 100 | fair | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Above typical Show detailsSector percentile: 71 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
3 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
The company aims for approximately 30% annual revenue growth over 2025.
Stated in 2 of last 2 quarters. Revenue grew from $6.7M in 2025-Q1 to $9.6M in 2026-Q1, indicating progress towards the 30% annual growth target. The trajectory shows delivering on the stated growth priority.
“The Company is reiterating revenue guidance of approximately 30% annual revenue growth over 2025.”
“The Company is providing revenue guidance of approximately 30% annual revenue growth over 2025.”
Focus on enhancing gross profit margins through operational efficiencies.
Stated in 3 of last 3 quarters. Gross profit increased from $7.5M in 2025-Q3 to $8.4M in 2026-Q1, showing improvement in margins. The trajectory indicates delivering on the margin improvement focus.
Aim to reduce net cash usage through operational efficiencies and cost management.
Newly stated in 2025-Q2. The company has not provided updated figures for net cash usage in subsequent quarters, indicating limited progress in reducing cash usage. The trajectory remains unclear without further data.
“Net cash usage for the remainder of the year to be between approximately $3.9 and $4.4 million.”
Results of Operations and Financial Condition. On March 19, 2026, electroCore, Inc. (the “Company”) issued a press release (i) announcing its financial results for the year ended December 31, 2025, and (ii) providing guidance for the full year of 2026. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated by reference. Except for information relating to Adjusted EBITDA net loss from operations and its reconciliation to generally accepted accounting principles (GAA…
of this Current Report on Form 8-K, Exhibit 99.1, and Exhibit 99.2, shall not be incorporated by reference into any filing with the Securities and Exchange Commission (the “SEC”) made by the Company, whether made before or after the date hereof, except as shall be expressly set forth by reference in such filing. The financial information set forth in this Current Report on Form 8-K, Exhibit 99.1, and Exhibit 99.2 reflects the Company’s current preliminary financial estimates, is subject to th…
Results of Operations and Financial Condition. On November 5, 2025, electroCore, Inc. (the “Company”) issued a press release (i) announcing its financial results for the quarter ended September 30, 2025, and (ii) providing updated guidance for the fourth quarter and full year of 2025. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated by reference. Except for information relating to Adjusted EBITDA net loss from operations and its reconciliation to generally ac…
Other Events. Private Placement On September 30, 2025, electroCore, Inc. (the “Company”) entered into securities purchase agreements with certain institutional and accredited investors (the “Private Agreements”), which collectively provided for the sale by the Company of 360,737 shares (the “Private Shares”) of common stock of the Company, par value $0.001 per share (the “Common Stock”). The Private Shares were issued at a price of $5.145 per share, in satisfaction of certain outstanding obli…
“Gross profit increased to $8.4M in 2026-Q1 from $8.2M in 2025-Q4.”
“Gross profit was $8.2M.”
“Gross profit was $7.5M.”